We also demonstrated the benefit of B4GALNT1 depletion in PD-1-targeted immunotherapy, which enhances the understanding of HCC progression and provides a novel auxiliary strategy for HCC immunotherapy. Here, PDCD1 is linked to hepatocellular carcinoma.